BR112015009638A2 - inibidores de glicosidase e usos dos mesmos - Google Patents

inibidores de glicosidase e usos dos mesmos

Info

Publication number
BR112015009638A2
BR112015009638A2 BR112015009638A BR112015009638A BR112015009638A2 BR 112015009638 A2 BR112015009638 A2 BR 112015009638A2 BR 112015009638 A BR112015009638 A BR 112015009638A BR 112015009638 A BR112015009638 A BR 112015009638A BR 112015009638 A2 BR112015009638 A2 BR 112015009638A2
Authority
BR
Brazil
Prior art keywords
compounds
glycosidase inhibitors
prodrugs
deficiency
provides
Prior art date
Application number
BR112015009638A
Other languages
English (en)
Inventor
J Vocacllo Davd
J Mceachern Ernest
G Selnck Harold
Dang Qun
Kaul Ramesh
Zhou Yuanx
Original Assignee
Alectos Therapeutics Inc
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alectos Therapeutics Inc, Merck Sharp & Dohme filed Critical Alectos Therapeutics Inc
Publication of BR112015009638A2 publication Critical patent/BR112015009638A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/06—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing nitrogen as ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)

Abstract

resumo da patente de invenã§ã£o para: “inibidores de glicosidase e usos dos mesmos". a invenã§ã£o proporciona compostos com permeabilidade aumentada para inibir seletivamente as glicosidases, prã³-fã¡rmacos dos compostos, e composiã§ãµes farmacãªuticas incluindo os compostos ou prã³-fã¡rmacos dos compostos. a invenã§ã£o tambã©m proporciona mã©todos de tratamento de doenã§as e distãºrbios relacionados com a deficiãªncia ou a superexpressã£o de o-glcnacase, acumulaã§ã£o ou deficiãªncia de o-glcnac.
BR112015009638A 2012-10-31 2013-10-30 inibidores de glicosidase e usos dos mesmos BR112015009638A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261720708P 2012-10-31 2012-10-31
PCT/CA2013/050822 WO2014067003A1 (en) 2012-10-31 2013-10-30 Glycosidase inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
BR112015009638A2 true BR112015009638A2 (pt) 2017-07-04

Family

ID=50626257

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015009638A BR112015009638A2 (pt) 2012-10-31 2013-10-30 inibidores de glicosidase e usos dos mesmos

Country Status (10)

Country Link
US (1) US9695197B2 (pt)
EP (1) EP2914604A4 (pt)
JP (2) JP2015534991A (pt)
KR (1) KR20150079711A (pt)
CN (1) CN104837845B (pt)
AU (1) AU2013337570B2 (pt)
BR (1) BR112015009638A2 (pt)
CA (1) CA2890115A1 (pt)
RU (1) RU2672873C2 (pt)
WO (1) WO2014067003A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010012107A1 (en) 2008-08-01 2010-02-04 Simon Fraser University Selective glycosidase inhibitors and uses thereof
WO2011140640A1 (en) 2010-05-11 2011-11-17 Simon Fraser University Selective glycosidase inhibitors and uses thereof
EP2638052B1 (en) 2010-11-08 2017-03-22 Alectos Therapeutics, Inc. Selective glycosidase inhibitors and uses thereof
CN103339138B (zh) 2010-12-23 2016-08-31 阿勒克图治疗公司 选择性糖苷酶抑制剂及其用途
US8927507B2 (en) 2011-03-24 2015-01-06 Ernest J. McEachern Selective glycosidase inhibitors and uses thereof
EP2691407B1 (en) 2011-03-31 2017-02-22 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
WO2013000086A1 (en) 2011-06-27 2013-01-03 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
MX364602B (es) 2011-06-27 2019-05-02 Alectos Therapeutics Inc Inhibidores selectivos de glicosidasa y usos de los mismos.
WO2013000085A1 (en) 2011-06-27 2013-01-03 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
EP2890675A4 (en) 2012-08-31 2016-01-13 Alectos Therapeutics Inc GLYCOSIDASE INHIBITORS AND USES THEREOF
WO2014032185A1 (en) 2012-08-31 2014-03-06 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
WO2014067003A1 (en) 2012-10-31 2014-05-08 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
WO2014100934A1 (en) 2012-12-24 2014-07-03 Merck Sharp & Dohme Corp. Glycosidase inhibitors and uses thereof
CN114174263A (zh) * 2019-05-10 2022-03-11 阿勒克图治疗公司 非溶酶体葡糖神经酰胺酶抑制剂及其用途
WO2024083820A1 (en) 2022-10-18 2024-04-25 Institut National de la Santé et de la Recherche Médicale Method and composition for determining the level of o-glcnacylation in horses

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS423500Y1 (pt) 1964-02-29 1967-03-01
DE2632243C3 (de) 1976-07-17 1979-08-30 Heidelberger Druckmaschinen Ag, 6900 Heidelberg Auf variable Bogenlängen einstellbare Umführtrommel für Druckmaschinen
SU703531A1 (ru) * 1977-09-02 1979-12-15 Институт Химии Нефти И Природных Солей Ан Казахской Сср Способ получени изоксазолинов, конденсированных с гетероциклическими соединени ми
DE3620645A1 (de) 1985-12-20 1987-07-02 Bayer Ag 3-amino-4,5-dihydroxypiperidine, verfahren zu ihrer herstellung und ihre verwendung
JPS6461459A (en) 1987-08-28 1989-03-08 Nippon Shinyaku Co Ltd Moranoline derivative
JPH01180894A (ja) 1988-01-07 1989-07-18 Wako Pure Chem Ind Ltd アミノ糖誘導体の新規な製造法
GB8900719D0 (en) 1989-01-13 1989-03-08 Nycomed As Compounds
US5079254A (en) 1990-06-04 1992-01-07 Merrell Dow Pharmaceuticals Inc. Derivatives of 6-aminooctahydroindolizinetriol
WO1992003415A1 (en) 1990-08-14 1992-03-05 Nova Pharmaceutical Corporation Protein kinase c modulators
US5276120A (en) 1991-05-30 1994-01-04 The Scripps Research Institute Process for forming omega-deuxy-azasugars
US6291657B1 (en) 1993-05-13 2001-09-18 Monsanto Company Deoxygalactonojirimycin derivatives
US5451679A (en) 1994-03-08 1995-09-19 G. D. Searle & Co. 2-chloro and 2-bromo derivatives of 1,5-iminosugars
JPH07316178A (ja) 1994-05-25 1995-12-05 Sankyo Co Ltd 糖アミノオキサゾリン類
CN1131672A (zh) 1994-11-22 1996-09-25 生化学工业株式会社 氨基环戊烷衍生物
CA2235415A1 (en) 1995-09-08 1997-03-13 Novo Nordisk A/S 2-alkylpyrrolidines
ATE234092T1 (de) 1995-09-08 2003-03-15 Novo Nordisk As 2-alkylpyrrolidine
JPH09132585A (ja) 1995-11-10 1997-05-20 Shin Etsu Chem Co Ltd 新規アミノ糖及びキトオリゴ糖又はその類似オリゴ糖の製造方法
US6407103B2 (en) 1998-04-21 2002-06-18 Bristol-Myers Squibb Pharma Company Indeno [1,2-c] pyrazol-4-ones and their uses
JPH11349541A (ja) 1998-06-08 1999-12-21 Sankyo Co Ltd アロサミゾリン誘導体の新規な中間体
GB9818732D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Collection of compounds
US6774140B1 (en) 1999-05-11 2004-08-10 The Scripps Research Institute Iminocyclitol inhibitors of hexoaminidase and glycosidase
ATE487697T1 (de) 1999-05-11 2010-11-15 Scripps Research Inst Iminocyclitol-inhibitoren von hexoaminidase und glycosidase
FR2817472B1 (fr) 2000-12-06 2003-01-03 Oreal Composition de teinture d'oxydation a base de 1-(4-aminophenyl)pyrrolidines substituees au moins en position 2 et 3 et procede de teinture de mise en oeuvre
JP4036755B2 (ja) 2001-03-14 2008-01-23 電気化学工業株式会社 ヒアルロン酸又はヒアルロン酸誘導体の製造法
JP4233262B2 (ja) 2001-03-14 2009-03-04 生化学工業株式会社 カルバ糖アミン誘導体及びそれを用いるグリコシダーゼ阻害剤
JP4363183B2 (ja) 2001-06-08 2009-11-11 三菱化学株式会社 アザ糖化合物
JP4866515B2 (ja) 2001-07-02 2012-02-01 生化学工業株式会社 糖オキサゾリン誘導体の製造方法
HUP0400659A3 (en) 2001-07-24 2005-06-28 Zhu Zhou Woodbridge Methods, compositions and kits relating to chitinases and chitinase-like molecules and inflammatory disease
US20070066543A1 (en) 2003-05-22 2007-03-22 The Hospital For Sick Children Treatment of tay sachs or sandhoff diseases by enhancing hexosaminidase activity
CN1548053A (zh) 2003-05-23 2004-11-24 华晶基因技术有限公司 黄芩甙作为治疗焦虑症的药物的新用途
MXPA06003161A (es) 2003-09-16 2006-06-05 Astrazeneca Ab Derivados de quinazolina.
CA2553866A1 (en) 2004-01-20 2005-08-11 Optimer Pharmaceuticals, Inc. Treatment of degenerative cartilage conditions in a mammal with glycosi dase inhibitors
EP1734821A4 (en) 2004-04-14 2011-07-06 Uab Research Foundation ACTIVATORS OF HEXOSAMIN BINOSYNTHESIS AS AN INHIBITORS FOR INDUCED DAMAGE CAUSED BY ISCHEMIC SHOCK OR HEMORRHAGIC SHOCK
TW200602314A (en) 2004-05-28 2006-01-16 Tanabe Seiyaku Co A novel pyrrolidine compound and a process for preparing the same
EP1773812A1 (en) 2004-07-23 2007-04-18 Bayer CropScience S.A. 3-pyridinylethylcarboxamide derivatives as fungicides
JP4023500B2 (ja) 2004-08-03 2007-12-19 ソニー株式会社 イヤホンアンテナ
CA2579143A1 (en) 2004-09-13 2006-03-23 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7884115B2 (en) 2004-09-28 2011-02-08 Allergan, Inc. Methods and compositions for the treatment of pain and other neurological conditions
EP1869060B1 (en) * 2005-03-01 2012-08-15 Simon Fraser University Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof
AT502145B1 (de) 2005-03-24 2012-01-15 Univ Graz Tech Glycosidase-hemmendes iminoalditol
US7820699B2 (en) 2005-04-27 2010-10-26 Hoffmann-La Roche Inc. Cyclic amines
TW200800220A (en) 2005-10-26 2008-01-01 Boehringer Ingelheim Int New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds
WO2007067515A2 (en) 2005-12-05 2007-06-14 Academia Sinica Novel five-membered iminocyclitol derivatives as selective and potent glycosidase inhibitors: new structures for antivirals and osteoarthritis therapeutics
CN101595111A (zh) * 2006-08-31 2009-12-02 西蒙·弗雷瑟大学 选择性糖苷酶抑制剂及其用途
CA2661582C (en) 2006-08-31 2015-09-29 Simon Fraser University Selective glycosidase inhibitors and uses thereof
US8258307B2 (en) 2006-11-07 2012-09-04 University Of Tokyo Amide compound or salt thereof, and biofilm inhibitor, biofilm remover and disinfectant containing the same
WO2010012107A1 (en) 2008-08-01 2010-02-04 Simon Fraser University Selective glycosidase inhibitors and uses thereof
CA2732335A1 (en) 2008-08-01 2010-02-04 Simon Fraser University Selective glycosidase inhibitors and uses thereof
EP2323651A2 (en) 2008-08-05 2011-05-25 Summit Corporation Plc Compounds for the treatment of flaviviral infections
EP2323652A2 (en) 2008-08-06 2011-05-25 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
EP2344452A4 (en) 2008-09-16 2012-03-14 Univ Fraser Simon SELECTIVE GLYCOSIDASE HEMMER AND ITS USE
WO2010049678A2 (en) 2008-10-31 2010-05-06 Summit Corporation Plc Treatment of energy utilization diseases
AT507745B1 (de) 2008-12-16 2012-01-15 Forschungsholding Tu Graz Gmbh Fluorophile glykosidasehemmer
WO2011060397A1 (en) 2009-11-16 2011-05-19 Schering Corporation Substituted amino heterocycles useful as hiv antagonists
EP2566876A4 (en) * 2010-05-06 2014-01-08 Univ Fraser Simon METHOD AND COMPOUNDS FOR INHIBITING GLYCOSYL TRANSFERASES
WO2011140640A1 (en) * 2010-05-11 2011-11-17 Simon Fraser University Selective glycosidase inhibitors and uses thereof
WO2012061971A1 (en) 2010-11-08 2012-05-18 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
WO2012061972A1 (en) 2010-11-08 2012-05-18 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
EP2638052B1 (en) 2010-11-08 2017-03-22 Alectos Therapeutics, Inc. Selective glycosidase inhibitors and uses thereof
TW201249848A (en) * 2010-11-08 2012-12-16 Merck Sharp & Dohme Selective glycosidase inhibitors and uses thereof
CN103339138B (zh) * 2010-12-23 2016-08-31 阿勒克图治疗公司 选择性糖苷酶抑制剂及其用途
GB201103526D0 (en) 2011-03-02 2011-04-13 Summit Corp Plc Selective glycosidase inhibitors and uses thereof
CA2830882C (en) 2011-03-22 2021-03-16 Dinesh Barawkar Substituted fused tricyclic compounds, compositions and medicinal applications thereof
US8927507B2 (en) 2011-03-24 2015-01-06 Ernest J. McEachern Selective glycosidase inhibitors and uses thereof
EP2691407B1 (en) 2011-03-31 2017-02-22 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
WO2012129802A1 (en) 2011-03-31 2012-10-04 Alectos Therapeutics Inc. Pyrano[3,2-d]thiazol derivatives and uses as selective glycosidase inhibitors thereof
WO2013000086A1 (en) 2011-06-27 2013-01-03 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
MX364602B (es) 2011-06-27 2019-05-02 Alectos Therapeutics Inc Inhibidores selectivos de glicosidasa y usos de los mismos.
WO2013000085A1 (en) 2011-06-27 2013-01-03 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
US9126957B2 (en) 2011-08-18 2015-09-08 Merck Sharp & Dohme Corp. Selective glycosidase inhibitors and uses thereof
CA2845149C (en) 2011-08-25 2019-12-31 Merck Patent Gmbh Pyrano[3,2-d] [1,3]thiazole as glycosidase inhibitors
EP2847199B1 (en) 2012-05-08 2017-10-25 Merck Sharp & Dohme Corp. Permeable glycosidase inhibitors and uses thereof
EP2890679A4 (en) 2012-08-31 2016-05-04 Alectos Therapeutics Inc GLYCOSIDASE INHIBITORS AND USES THEREOF
US9522883B2 (en) 2012-08-31 2016-12-20 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
EP2890675A4 (en) 2012-08-31 2016-01-13 Alectos Therapeutics Inc GLYCOSIDASE INHIBITORS AND USES THEREOF
WO2014032185A1 (en) 2012-08-31 2014-03-06 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
WO2014067003A1 (en) 2012-10-31 2014-05-08 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
WO2014100934A1 (en) 2012-12-24 2014-07-03 Merck Sharp & Dohme Corp. Glycosidase inhibitors and uses thereof

Also Published As

Publication number Publication date
AU2013337570A1 (en) 2015-05-14
EP2914604A1 (en) 2015-09-09
JP2018172405A (ja) 2018-11-08
RU2015120556A (ru) 2016-12-20
US9695197B2 (en) 2017-07-04
EP2914604A4 (en) 2016-07-20
AU2013337570B2 (en) 2018-01-18
CN104837845A (zh) 2015-08-12
JP2015534991A (ja) 2015-12-07
US20150291620A1 (en) 2015-10-15
WO2014067003A1 (en) 2014-05-08
RU2672873C2 (ru) 2018-11-20
CN104837845B (zh) 2018-08-28
KR20150079711A (ko) 2015-07-08
CA2890115A1 (en) 2014-05-08

Similar Documents

Publication Publication Date Title
BR112015009638A2 (pt) inibidores de glicosidase e usos dos mesmos
BR112013033098B8 (pt) inibidores de glicosidade seletivos e usos dos mesmos
MX343822B (es) Inhibidores selectivos de glucosidasas, y usos de los mismos.
MX336611B (es) Inhibidores selectivos de glucosidasas y sus usos.
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
MA32393B1 (fr) Composés et compositions servant d'inhibiteurs de kinases
BR112013027774A2 (pt) novos compostos como moduladores de proteína quinases
BR112015028214A2 (pt) inibidores de acc e usos dos mesmos
UY33597A (es) Compuestos y composiciones como inhibidores de la trk
PH12015500689B1 (en) Azaquinazoline inhibitors of atypical protein kinase c
BR112014017751A8 (pt) compostos inibidores de metaloenzima, métodos de inibir e modular a atividade de metaloenzina, composições contendo os ditos compostos e uso dos ditos compostos
TN2012000081A1 (en) Compounds and compositions as protein kinase inhibitors
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201500362A1 (ru) Ингибиторы rho-киназы
BR112012027034A2 (pt) inibidores da arginase e suas aplicações terapêuticas
WO2014031928A3 (en) Heterocyclic modulators of hif activity for treatment of disease
EA201391390A1 (ru) Циклопропиламины в качестве ингибиторов lsd
EA201171493A1 (ru) МОТИВЫ ХИМИЧЕСКИХ МОДИФИКАЦИЙ ДЛЯ ИНГИБИТОРОВ И МИМЕТИКОВ мкРНК
EA201491151A1 (ru) Соединения, ингибирующие металлоферменты
BR112015029090A2 (pt) compostos de 3,4-di-hidroisoquinolin-2(1h)-ila
IN2014CN04558A (pt)
EA201200570A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MX2012001134A (es) Composiciones y metodos para inhibicion de la via jak.
BR112015023878A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112013033836A2 (pt) terapia de combinação

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements